Irl Hirsch
Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1881770642
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Abbott at 44.3% of the total. Among endocrinology, diabetes & metabolism clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $893.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$85K
- Roche Diabetes Care GmbH$39K
- F. Hoffmann-la Roche AG$15K
- Embecta Corp.$13K
- Lifescan, Inc.$13K
- Roche Diabetes Care, Inc.$10K
- plus $17K from 8 others
Across 186 payments — averaging $11,839 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$870K
- Insulet Corporation$567K
- Tandem Diabetes Care, Inc.$439K
- Mannkind Corporation$165K
- Sequel Med Tech, LLC$106K
- Gilead$29K
- plus $26K from 2 others
What the payments were for
- Consulting fees$99,64352%
- Speaking & faculty fees$31,42516%
- Travel & lodging$53,79228%
- Food & beverage$7,1094%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 137 | $85,029 |
| Roche Diabetes Care GmbH | 19 | $39,273 |
| F. Hoffmann-la Roche AG | 10 | $14,642 |
| Embecta Corp. | 4 | $13,267 |
| Lifescan, Inc. | 9 | $13,168 |
| Roche Diabetes Care, Inc. | 2 | $9,552 |
| Mannkind Corporation | 16 | $8,993 |
| Vertex | 12 | $5,849 |
| Medtronic | 1 | $2,000 |
| Roche Diagnostics Corporation | 1 | $90 |
| BD | 1 | $74 |
| Genentech, Inc. | 1 | $38 |
| Lexicon Pharmaceuticals, Inc. | 1 | $38 |
| Sequel Med Tech, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accu-Chek Inform II Instrument with RF card$35,741
- FREESTYLE LIBRE 3$30,196
- FreeStyle Libre Pro$21,403
- FreeStyle Libre$20,036
- DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessori$10,436
- AFREZZA$8,487
- Accu-Chek Instruments$2,220
- InPen$2,000
- FreeStyle Lite system$136
How this compares
$192,029 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $94,328 |
| JardianceEmpagliflozin | 26 | $40,727 |
| MounjaroTirzepatide | 13 | $15,041 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $14,681 |
| LyumjevInsulin Lispro-Aabc | 15 | $10,674 |
| HumalogInsulin Lispro | 45 | $10,006 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,136 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $7,200 |
| Novolog FlexpenInsulin Aspart | 23 | $6,217 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,246 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $2,252 |
| Atorvastatin Calcium | 93 | $1,001 |
| Levothyroxine Sodium | 52 | $858 |
| Ezetimibe | 31 | $705 |
| Rosuvastatin Calcium | 38 | $667 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Seattle
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- William HagopianSeattle$30K
- Mahnaz MellatiSeattle$28K
- Alan ChaitSeattle$21K
- Jose GarciaSeattle$12K
- Carla GreenbaumSeattle$7K
- Tracy TyleeSeattle$7K
- Asha PathakSeattle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.